Paul A. Clark

This study shows that optimized spatially heterogeneous radiopharmaceutical therapy enhances immune checkpoint blockade response in poorly immunogenic tumors by promoting T cell activation and infiltration.

This study shows that heterogeneous radiation dose in tumors enhances anti-tumor immunity and correlates with better clinical outcomes in prostate cancer patients.

This study compares the immune effects of alpha- and beta-particle emitting radiopharmaceuticals combined with immune checkpoint inhibitors in murine tumor models, finding distinct mechanisms of action based on radiation type.

The paper identifies SUZ12's nucleic acid-binding domain as critical for regulating PRC2 activity in H3 K27M gliomas, showing how it constrains enzymatic function and maintains targeted gene silencing.

This study examines how different radionuclides affect the type I interferon response in tumor models and shows that 225Ac enhances immunotherapy response via STING-dependent mechanisms.